- Home
- AMBO vs GLMD Comparison
AMBO vs GLMD Comparison
Compare AMBO & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- GLMD
- Stock Information
- Founded
- AMBO 2000
- GLMD 2000
- Country
- AMBO United States
- GLMD Israel
- Employees
- AMBO N/A
- GLMD N/A
- Industry
- AMBO Other Consumer Services
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- GLMD Health Care
- Exchange
- AMBO Nasdaq
- GLMD Nasdaq
- Market Cap
- AMBO 5.1M
- GLMD 4.6M
- IPO Year
- AMBO 2010
- GLMD 2014
- Fundamental
- Price
- AMBO $1.42
- GLMD $2.97
- Analyst Decision
- AMBO
- GLMD
- Analyst Count
- AMBO 0
- GLMD 0
- Target Price
- AMBO N/A
- GLMD N/A
- AVG Volume (30 Days)
- AMBO 157.1K
- GLMD 47.4K
- Earning Date
- AMBO 12-27-2024
- GLMD 01-03-2025
- Dividend Yield
- AMBO N/A
- GLMD N/A
- EPS Growth
- AMBO N/A
- GLMD N/A
- EPS
- AMBO N/A
- GLMD N/A
- Revenue
- AMBO $9,163,000.00
- GLMD N/A
- Revenue This Year
- AMBO N/A
- GLMD N/A
- Revenue Next Year
- AMBO N/A
- GLMD N/A
- P/E Ratio
- AMBO N/A
- GLMD N/A
- Revenue Growth
- AMBO N/A
- GLMD N/A
- 52 Week Low
- AMBO $1.00
- GLMD $2.56
- 52 Week High
- AMBO $6.30
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- AMBO 40.93
- GLMD 50.01
- Support Level
- AMBO $1.35
- GLMD $2.81
- Resistance Level
- AMBO $1.56
- GLMD $3.35
- Average True Range (ATR)
- AMBO 0.18
- GLMD 0.26
- MACD
- AMBO -0.05
- GLMD 0.06
- Stochastic Oscillator
- AMBO 7.55
- GLMD 59.47
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.